Drugs / CARE T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04715191 | May 2024 → Aug 2026 overdue | Wilms tumor, liposarcoma, liver cancer, rhabdoid tumor +2 | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARE T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04715191 ↗ |
| Modality | Cell therapy | “This study will test T cells genetically engineered with a GPC3-CAR and IL15 plus IL21 (CARE T cells) in patients with GPC3-positive solid tumors.” NCT04715191 ↗ |
| Target | GPC3 | “Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells” NCT04715191 ↗ |